MENLO PARK, CA – January 27, 2014 – AtheroMed, a developer of innovative catheter technologies for treating peripheral artery disease (PAD), today announced that it has received FDA clearance to market the Phoenix Atherectomy System®, which allows physicians to treat PAD with a low profile atherectomy catheter that continuously removes diseased material as it is debulked and does not require specialized capital equipment.
“Peripheral artery disease, especially lesions located below the knee, can be challenging to treat, even with currently available technologies,” said Dr. Thomas Davis, Director of the Cardiac Catheterization Lab and Director of Peripheral Interventions and Disease at St. John Hospital and Medical Center in Detroit, MI. “My experience with the Phoenix device during the EASE clinical study was extremely positive, and I am excited that the device is now available as it will allow me to debulk small vessels that I may not have been able to treat in the past.”
Read more: http://www.atheromedinc.com/atheromed-announces-fda-clearance-to-market-the-phoenix-atherectomy-system-for-treating-peripheral-artery-disease/
AtheroMed Announces FDA Clearance to Market the Phoenix Atherectomy System for Treating Peripheral Artery Disease
TetraLogic Announces Licensing and Research Collaboration With Walter and Eliza Hall Institute of Medical Research
MALVERN, Pa., Jan. 21, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has entered into a research collaboration with the Walter and Eliza Hall Institute of Medical Research to examine TetraLogic's SMAC-Mimetic birinapant in viral infections. Preclinical studies performed at the WEHI have indicated that SMAC-Mimetics decrease the viral burden in mice with human Hepatitis B Virus (HBV) by inducing apoptosis of virally infected hepatocytes while sparing the non-infected cells.
Via PR Newswire:
SUNNYVALE, Ca., Jan. 13, 2014 /PRNewswire/ -- Silk Road Medical, Inc., a developer of advanced devices for the treatment of Carotid Artery disease, announced today the appointment of Sumaira Macdonald, MD, PhD to the position of Chief Medical Officer effective immediately. In this new role, Dr. Macdonald will direct the company's scientific and technical agenda and lead research in ground breaking endovascular interventions for the prevention and treatment of stroke.
Santa Clara, CA, January 13th, 2014 - ProteinSimple today launched Sally Sue and Peggy Sue, the next generation of high throughput Simple Western instruments. These instruments drive the sensitivity of the current high throughput Simple Western systems to performance levels well beyond any traditional Western.
OncoMed Pharmaceuticals Initiates First Phase 1b Clinical Trial of OMP-54F28 (Fzd8-Fc) With Nab-Paclitaxel (Abraxane(R)) and Gemcitabine in Pancreatic Cancer
REDWOOD CITY, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it has started a multi-center Phase 1b clinical trial of its first-in-class Wnt-pathway-targeting decoy receptor OMP-54F28 (Fzd8-Fc) with nab-paclitaxel (Abraxane®) and gemcitabine in pancreatic cancer. This trial is the first of three Phase 1b trials for OMP-54F28 expected to begin patient enrollment in the next few months as part of OncoMed's collaboration with Bayer Pharma AG. This study follows on the recent initiation of OncoMed's Phase 1b program for the Wnt-pathway-targeting antibody vantictumab (OMP-18R5, Anti-Fzd7).
SANTA CLARA, Calif., Jan. 8, 2014 , PRNewswire -- ProteinSimple today introduced Wes, another revolutionary re-invention of the Western blot. Wes is the bold evolution of the popular Simple Western family of instruments, delivering simplicity and performance like no product before it. With just 30 minutes of sample prep, Wes will analyze up to 25 samples in under 3 hours and he will do it all for less than the price of a high-end Western imager. Wes also introduces an innovative suite of consumables that streamline assay workflow and delivers sensitivity that is better than any traditional Western.
Soft Tissue Regeneration, Inc. Announces Financing and Appoints New Members to Board of Directors